Clinical characteristics of patients: group A (watch and wait)
| . | . | All patients . | FL . | MCL . | nMZL . |
|---|---|---|---|---|---|
| n | 21 | 15 | 3 | 3 | |
| Median (range) age | years | 53 (30-78) | 44 (30-60) | 77 (56-78) | 68 (57-75) |
| Stage | III A | 10 | 9 | 0 | 1 |
| IV A | 11 | 6 | 3 | 2 | |
| Risk score, n | IPI 1/5: 13 | FLIPI 1/5: 5 | MIPI 5-6: 1 | IPI 1/5: 1 | |
| IPI 2-3/5: 8 | FLIPI 2/5: 8 | MIPI 6-7: 2 | IPI 2/5: 2 | ||
| FLIPI 3/5: 2 | |||||
| Median (range) time from diagnosis to first vaccination | months | 13 (5-105) | 13 (5-105) | 11 (7-15) | 18 (8-27) |
| Remission status | SD | 17 | 11 | 3 | 3 |
| PD | 4 | 4 | 0 | 0 | |
| FcγRIIIa genotype | 158FF | 9 | 6 | 2 | 1 |
| 158FV | 8 | 6 | 1 | 1 | |
| 158VV | 3 | 2 | 0 | 1 |
| . | . | All patients . | FL . | MCL . | nMZL . |
|---|---|---|---|---|---|
| n | 21 | 15 | 3 | 3 | |
| Median (range) age | years | 53 (30-78) | 44 (30-60) | 77 (56-78) | 68 (57-75) |
| Stage | III A | 10 | 9 | 0 | 1 |
| IV A | 11 | 6 | 3 | 2 | |
| Risk score, n | IPI 1/5: 13 | FLIPI 1/5: 5 | MIPI 5-6: 1 | IPI 1/5: 1 | |
| IPI 2-3/5: 8 | FLIPI 2/5: 8 | MIPI 6-7: 2 | IPI 2/5: 2 | ||
| FLIPI 3/5: 2 | |||||
| Median (range) time from diagnosis to first vaccination | months | 13 (5-105) | 13 (5-105) | 11 (7-15) | 18 (8-27) |
| Remission status | SD | 17 | 11 | 3 | 3 |
| PD | 4 | 4 | 0 | 0 | |
| FcγRIIIa genotype | 158FF | 9 | 6 | 2 | 1 |
| 158FV | 8 | 6 | 1 | 1 | |
| 158VV | 3 | 2 | 0 | 1 |
IPI indicates International Prognostic Index; FLIPI, Follicular Lymphoma International Prognostic Index; and MIPI, Mantle Cell Lymphoma International Prognostic Index.